78.76
-0.51(-0.64%)
Currency In USD
Address
2855 Gazelle Court
Carlsbad, CA 92010
United States of America
Phone
760 931 9200
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
1069
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| Brett Monia | Founder, Chief Executive Officer & Director | 2.09M | 1961 |
| C. Frank Bennett | Executive VP & Chief Scientific Officer | 651,639 | 1957 |
| Kyle Jenne | Executive VP & Chief Global Product Strategy Officer | 804,966 | 1976 |
| Patrick R. O'Neil | Executive Vice President, Chief Legal Officer, General Counsel & Corporate Secretary | 971,520 | 1974 |
| Richard S. Geary | Executive VP & Chief Development Officer | 1.01M | 1958 |
| Elizabeth L. Hougen | Executive VP of Finance & CFO | 1.16M | 1962 |
| Darren Gonzales | Chief Accounting Officer & Senior Vice President | 0 | N/A |
| D. Wade Walke | Senior Vice President of Investor Relations | 0 | N/A |
| Hayley Soffer | Vice President of Corporate Communications | 0 | N/A |
| Tracy Berns | Senior VP and Chief Compliance & Quality Assurance Officer | 0 | N/A |
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.